The UNC Institutional Biosafety Committee was established to review recombinant DNA research conducted at or sponsored by UNC for compliance with the National Institutes of Health (NIH) guidelines and approve those research projects that are found to conform with the NIH Guidelines. The Institutional Biosafety Committee meets the requirements of the North Carolina Open Meetings Law.
On behalf of the institution, the Institutional Biosafety Committee is responsible for:
Reviewing recombinant DNA research conducted at or sponsored by the institution for compliance with the NIH Guidelines as specified in Section III, Experiments Covered by the NIH Guidelines, and approving those research projects that are found to conform with the NIH Guidelines. This review shall include: (i) independent assessment of the containment levels required by the NIH Guidelines for the proposed research; (ii) assessment of the facilities, procedures, practices, and training and expertise of personnel involved in recombinant DNA research; (iii) ensuring that all aspects of Appendix M have been appropriately addressed by the Principal Investigator; (iv) ensuring that no research participant is enrolled (see definition of enrollment in Section I-E-7) in a human gene transfer experiment until the RAC review process has been completed (see Appendix M-I-B, RAC Review Requirements); (v) for human gene transfer protocols selected for public RAC review and discussion, consideration of the issues raised and recommendations made as a result of this review and consideration of the Principal Investigator’s response to the RAC recommendations; (vi) ensuring that final IBC approval is granted only after the RAC review process has been completed (see Appendix M-I-B, RAC Review Requirements); and (vii) ensuring compliance with all surveillance, data reporting, and adverse event reporting requirements set forth in the NIH Guidelines.
Notifying the Principal Investigator of the results of the Institutional Biosafety Committee’s review and approval.
Lowering containment levels for certain experiments as specified in Section III-D-2-a, Experiments in which DNA from Risk Group 2, Risk Group 3, Risk Group 4, or Restricted Agents is Cloned into Nonpathogenic Prokaryotic or Lower Eukaryotic Host-Vector Systems.
Setting containment levels as specified in Sections III-D-4-b, Experiments Involving Whole Animals, and III-D-5, Experiments Involving Whole Plants.
Periodically reviewing recombinant DNA research conducted at the institution to ensure compliance with the NIH Guidelines.
Adopting emergency plans covering accidental spills and personnel contamination resulting from recombinant DNA research. Note: The Laboratory Safety Monograph describes basic elements for developing specific procedures dealing with major spills of potentially hazardous materials in the laboratory, including information and references about decontamination and emergency plans. The NIH and the Centers for Disease Control and Prevention are available to provide consultation and direct assistance, if necessary, as posted in the Laboratory Safety Monograph. The institution shall cooperate with the state and local public health departments by reporting any significant research-related illness or accident that may be hazardous to the public health.
Reporting any significant problems with or violations of the NIH Guidelines and any significant research related accidents or illnesses to the appropriate institutional official and NIH/OBA within 30 days, unless the Institutional Biosafety Committee determines that a report has already been filed by the Principal Investigator. Reports to NIH/OBA shall be sent to the Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985 (20817 for non-USPS mail), 301-496-9838, 301-496-9839 (fax).
The Institutional Biosafety Committee may not authorize initiation of experiments which are not explicitly covered by the NIH Guidelines until NIH (with the advice of the RAC when required) establishes the containment requirement.
Performing such other functions as may be delegated to the Institutional Biosafety Committee under Section IV-B-2, Institutional Biosafety Committee.
Institutional Biosafety Committee Membership List
Doug Cyr, PhD
Chair, Institutional Biosafety Committee and Professor, Cell & Development Biology
Victoria Baxter, DVM, PhD, DACLAM
Assistant Professor, Division of Comparative Medicine
Executive Director, Environment, Health and Safety
Interim Biosafety Officer, Environment, Health and Safety
Craig Fletcher, DVM, PhD, DACLAM
Director, Division of Comparative Medicine
Ilana Galex, DVM, DACLAM
Assistant Professor, Division of Comparative Medicine
Rachel Graham, PhD
Assistant Professor, Epidemiology
Associate Professor, Pharmacy
Orange Water & Sewer Authority
Stanley M. Lemon, PhD
Professor, Medicine, Microbiology and Immunology
Ann Matthysse, PhD
Professor, Department of Biology
Assistant Fire Chief, Chapel Hill Fire Department
Barbara Savoldo, MD, PhD
Research Professor, Pediatrics, Hematology and Oncology
Biosafety Specialist, Environment, Health and Safety (IBC Administrator)
Unless noted otherwise, the location for all meetings is Burnett-Womack 9001. Please note that access to the 9th floor of Burnett-Womack is currently access-controlled. To attend the meeting, please gather in the lobby on the ground floor by the front entrance and a member of the IBC will escort you to the meeting room at 3:25 p.m. Additionally, you can email the IBC directly at firstname.lastname@example.org ahead of time to schedule an escort.